Search academic texts

Registration Number

0219U003594, 0116U003575 , R & D reports

Title

Role of molecular genetic of somatic cells, pharmacological and chemical characteristics of ABO antigens and medicinal drugs in selection of individualized therapy programs in patients with chronic lymphoproliferative neoplasms

popup.stage_title

Head

Minchenko Zhanna; Liubarets Tatiana,

Registration Date

29-01-2019

Organization

State institution "National research centеr for radiation medicine of the National academy of medical sciences of Ukraine "

popup.description2

The object of the study is clinical and hematological, immunogenetic, molecular-cytogenetic characteristics of chronic lymphoproliferative neoplasms (ChLN), including chronic lymphocytic leukemia (CLL) and рlasma cell myeloma (PCM). Objective is to create the necessity of individualized therapy for patients based on the implementation of complex of criteria for the elaboration of treatment programs based on clinical and hematological, molecular and genetic, epigenetic parameters of somatic cells, pharmacological and chemical parameters of ABO antigens in pathogenesis of chronic lymphoprolyferative diseases. Methods of investigation - clinical, hematological, molecular cytogenetic, immunogenetic, immunological, statistical. Database includs 267 patients with ChLPN, among them 148 CLL and 119 PCM cases. In PCM patients a probable increase of the frequency of the TGF-alpha codon 10 T / T genotype and a probable increase of the incidence of phenotype B with deviation of IB gene balance in cases with chronic renal failure were revealed. In the model "antigen-antibody" in vitro an extension of the agglutination reaction time of bortezomib with glycoprotein B was established. For patients with blood groups O (I) and A (II) the balance is shifted towards the main reaction which causes the therapeutic effect (B1>>01>A1). In PCM patients the combination of the abnormalities of chromosome 13 (del13q34) with the translocation t(4; 14), and the translocation t(14; 16) with the abnormality of chromosome 16 is associated with the primary refractory disease or the minimal effectiveness of treatment with the development of complications (Ro Spearman = 0,33; p<0.05). In CLL patients with relapse and/or development of disease resistance deletions of chromosome 17 (17p13.1), chromosome 13 (del13q14), and monosomy of chromosome 13 prevailed. The increased level of IL-6 in ChLPN patients before the treatment was revealed. In resistent stage of disease the level of IL-6 and TNF-alpha varied in different ways: significantly (p <0.05) increased by 1.6 and 1,8 times in CLL patients and decreased, respectively, in 1.8 and 1.4 times (p <0.05) in PCM patients. On the basis of multicomponent research, a complex of criteria for prediction of the course of diseases for substantiation of ways of individualized therapy of ChLPN patients was developed.

Product Description

popup.authors

Балан Валентина Володимирівна
Бебешко Володимир Григорович
Дмитренко Олена Олександрівна
Мішаріна Жанна Анатоліївна
Сілаєв Юрій Олегович
Товстоган Анжела Олександрівна
Хоменко Віктор Іванович
Шляхтиченко Тетяна Юріївна

popup.nrat_date

2020-04-02